R&D Partner Content 3rd Process Development for Cell Therapies Summit In the dynamic cell therapy landscape, where financial challenges continue to prevail, the emphasis on innovative process development becomes pivotal.
R&D Partner Content GLP-1-Based Therapeutics Summit Advancing Specialized, Durable, & Efficacious GLP-1s & Investigating Commercial Opportunity to Crystallize Pipeline Strategy & Indication Expansion
R&D Partner Content Cell & Gene Therapy Pricing & Reimbursement Summit Unlocking Patient Access to Affordable Advanced Therapies
R&D Partner Content 6th Allogeneic Cell Therapies Summit Driving Potency, Efficacy & Durability of Universal Cell Therapies
R&D Partner Content The 3rd Next-Generation Conjugates Summit is back! Driving Innovation and Pioneering Novel Payload & Format Conjugate Design
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.